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Abstract
Background: Knee osteoarthritis (OA) is considered a major public health issue causing chronic disability
worldwide with the increasing number of aging people. In China and increasingly worldwide, many sufferers with
knee OA are using complementary and alternative medicine including herbal drug, herbal patch, acupuncture and
Tuina etc., to alleviate their symptoms. However, evidence gathered from systematic reviews or randomized
controlled trials (RCT) has only validated acupuncture for the management of osteoarthritic pain. Moreover, such
Traditional Chinese Medicine (TCM) methods above are commonly used in an integrative way. This trial is aimed to
compare the efficacy of an individually integrated TCM approach in the management of knee OA with other single
treatments as parallel randomized controls.
Methods/design: Five teaching hospitals will participate in this randomized controlled trial. 500 participants, 100 in
each hospital, will be randomly assigned to receive oral administration of a Chinese herbal drug (counter
osteophytes capsule), topical use of a Chinese herbal patch (Fufnag Zijin patch), acupuncture, Tuina and the
individually integrated TCM approach. The individually integrated TCM approach consists of basic treatment of oral
counter osteophytes capsule, variable use of Tuina, acupuncture and a herbal patch based on the severity of the
patient’s symptoms.
The interventions are given for a period of 4 weeks. The primary outcome measure is the self-reported total score
using the Western Ontario McMaster Universities Osteoarthritis Index (WOMAC). Secondary outcome measures
include patient and investigator global assessment of response to treatment, patient and investigator global
assessment of OA condition, WOMAC pain, stiffness, and physical function subscales, short-form 36 (SF-36) and
TCM assessment of OA condition measured by syndromes questionnaire. Mixed models and sensitivity analysis will
be used for the statistical analysis.
Discussion: The trial is designed to test the hypothesis that an individually integrated TCM approach is more
effective than four treatment modalities used separately. The major limitation of this study is lack of placebo
control and of double blinding.
Trial Registration: Chinese Cochrane Center ChiCTR-TRC-00000176
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Background
Osteoarthritis (OA), the most common form of arthritis,
is a chronic, degenerative, joint disease that affects
mostly middle-aged and older adults. OA is character-
ized by a series of pathological changes in the whole
joint, including cartilage loss, bone remolding, excess
synovial fluid secretion, capsular swelling, inflammation
in the synovium (synovitis), bone marrow lesions, mus-
cle weakness and atrophy resulting in bone thickening
and formation of bone growths or spurs that interfere
with joint movement [1,2].
Evidence gathered from a systematic review show that
herbal medicines, which appear relatively safe, may offer
a much-needed alternative, and merit further attention
[3]. Current therapies in China available for the treat-
ment of OA include: oral analgesics such as acetamino-
phen, ibuprofen, and topicals preparations including
both Western medicine and Traditional Chinese Medi-
cine (TCM) products. Acupuncture and Tuina have also
been used for the management of OA. Although such
TCM methods above have been regarded effective in
clinical experiences and case reports, high level evidence
has been rarely reported.
Only limited data are available on the efficacy and
cost-effectiveness of Traditional Chinese herbs in the
treatment of knee OA. According to TCM theory, OA
is known as the Bi syndrome (painful obstruction),
which means either the limbs or the joints are suffered
from pain and malfunction; and herbal therapy has
long been a standard treatment. The herbal drug can
be used by external application or by oral administra-
tion. The counter osteophytes capsule, an extract from
Radix Rehamanniae (Dihuang) and Herbal Cistanches
(Roucongrong), is a Traditional Chinese herb used for
symptomatic treatment of inflammation and pain in
osteoarthritis. The earliest report was by Liu who
reviewed the effect of counter osteophytes capsule on
the treatment of OA in 1,000 cases [4]. Our previous
study supported its efficacy in pain management of
OA [5].
The Fufang Zijin patch, containing active ingredients
extracted mainly from Kadsura Root-bark (Zijinpi)
Negundo Chastetree Fruit(Huangjinzi) and Rhubarb
(Dahuang), is also commonly used in China for the
treatment of OA. According to TCM theory, the Fufang
Zijin patch is indicated for the treatment of local joint
pain, swelling, numbness, difficulty in physical activities
due to the syndrome of “cold-dampness”, “meridian
obstruction”, and “blood stasis”.
Tuina is a very important component of TCM
together with acupuncture and herbal medicines. Tuina,
called ‘An Mo’ or medical massage in ancient times,
usually refers to the doctor using their hands to
manipulate the patient’s body surface by means of var-
ious forms of tuina maneuvers such as pushing, knead-
ing, rolling, wrenching, and flicking-plucking to relax
and dredge the meridians and promote Qi flowing and
blood circulating. Tuina is considered a natural treat-
ment and manual therapy. It is distinct from chiroprac-
tic, osteopathic and mobilization because Tuina is used
under the guidance of the basic theory of TCM. Among
alternative care consumers with OA, the most com-
monly used treatment was massage therapy (57%) [6].
Some reports documente similar massage therapy as
efficacious in the treatment of OA of the knee [7], but a
systematic review of recent trials failed to confirm its
efficacy [8].
In many Asian countries and increasing in western
countries, acupuncture is a very popular treatment for
OA. Systematic reviews and RCTs support the effective-
ness of acupuncture for OA pain [9,10].
Optimal management of OA calls for an individual
approach based on different constitutions of human
body [11]. The individually integrated TCM approach
in this study has been formed during 15 years of clini-
cal experience in Shuguang hospital affiliated to Shang-
hai university of TCM. The approach consists of a
basic treatment of orally administered Chinese herbal
drugs and varying use of Tuina, acupuncture and her-
bal patch, all based on the severity of the patient
symptoms.
We therefore initiated this study to compare the effi-
cacy of an individually integrated TCM approach, Chi-
nese herb counter osteophytes capsule, Fufang Zijin
patch, acupuncture and Tuina in the short-term, symp-
tomatic treatment of OA of the knee. We hypothesized
that the integrated TCM approach is more effective
than the four treatments, oral medication, topical patch,
acupuncture or Tuina, when used alone.
Methods/design
Study design
This is a prospective, five-center, parallel-group, rando-
mized controlled efficacy and safety study of individually
integrated TCM approach in subjects with knee OA.
After giving informed written consent, patients undergo
a treatment period of four weeks. Ethics approval was
received from Chinese Cochrane Center with the NO:
ChiCTRCTET2008-9.
Participants
All outpatients between 38 and 75 years of age who suf-
fer from painful osteoarthritis of the knee according to
American College of Rheumatology (ACR) criteria [12]
will be screened. Additional inclusion and exclusion cri-
teria are detailed in Table 1.
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Randomization
A total of 500 patients, 100 in each hospital, will be
recruited from eligible patients. They will be randomly
and blindly assigned to 5 different treating groups
through the globally multicentre online randomization
facility established by China Academy of Chinese Medi-
cal Sciences http://210.76.97.192:8080/cjbyj/.
Intervention
On Day 0 (Visit 1), patients will begin treatment with
either herbal drug, herbal patch, acupuncture, Tuina, or
integrative approach. On Day 14, patients will return for
an interim visit (Visit 2). On Day 28, the final visit will
take place (Visit 3). Thus, the duration of treatment is 4
weeks.
Oral administration of herbal drug
Participants in this group will receive counter osteo-
phytes capsule (approval NO:Z10980006, manufactured
by Jiangsu Kanion Pharmaceutical Co., Ltd) at a daily
dose of 5.25 g.
Topical application of herbal patch
The product, Fufang Zijin patch (approval NO:
Z19991106, manufactured by Shanghai LEY’s Pharma-
ceutical Co., Ltd), will be applied at bed time to the
right or left knee selected for the study and removed at
approximately 8 hours after application (not to exceed
12 hours of exposure time). The location (right or left
knee) and time of patch application and removal will be
recorded daily in a diary for compliance purposes.
Tuina
The manipulation will be performed according to estab-
lished standard operation procedure (SOP) (Table 2).
Acupuncture
Acupuncture will be performed according to previously
reported SOP [13,14].
Individually integrated Traditional Chinese Medicine
approach
The approach consist of basic treatment of oral counter
osteophytes capsule and varying use of Tuina, acupunc-
ture and herbal patch based on the severity of patient’s
symptoms. The differing individually integrated TCM
treatments are shown on the left column of Table 3.
The treatment combination (called “approach content”
in Table 3) used depends on the WOMAC characteris-
tics as listed in the right column of Table 3. The base-
line WOMAC determines the initial treatment, and the
ongoing WOMAC later in the trial determines the later
ongoing treatments in this arm of the trial.
Patients in all arms are allowed paracetamol as rescue
medication for breakthrough pain at a dose of 500 mg
up to a maximum of 2 g per day. The use of rescue
medication should not exceed 3 days in each week and
should not be taken within 48 hours of a follow up visit.
A count of returned tablets will be done at each visit.
Quality assurance
To ensure that treatments are of a high standard and
delivered in accordance with the trial protocol, thera-
pists responsible for application of Tuina and acupunc-
ture will attend a two-day training workshop on the
delivery of the treatment programs. They will also be
provided with a written protocol and standardized
recording documents. In addition, all treatments pro-
vided to patients will be carefully recorded. Although
patients, investigators, and therapists administering
treatment will not be blinded, those assessing the
Table 1 Additional inclusion and exclusion criteria
Additional inclusion criteria
Pain intensity of 20 mm or more by VAS in the previous 48 hours when
walking on a flat surface;
At least grade II to III on the Kellgren-Lawrence scale by an X-ray taken
within 6 months;
And reluctant to continue on previous drug but willing to change drug
treatment.
Exclusion criteria
Patients presenting with any of the following will be excluded from the study.
Grade I or Grade IV severity of the index knee based on the Kellgren and
Lawrence radiographic criteria as applicable;
Use of intra-articular injections or arthroscopy of the index knee within 3
months prior to screening;
Evidence of crystalline-induced synovitis in the index knee;
History, physical examination, or radiographic results suggestive of acute
inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, septic
arthritis, gout, pseudogout, fibromyalgia, systemic lupus erythematosus,
or other types of inflammatory arthritis of the index knee;
Pain in either knee of neurologic origin;
Signs of clinically important active inflammation in the index knee joint
including redness, warmth, and/or a large, bulging effusion with the loss
of normal contour at the screening and/or baseline visits;
History of acute inflammatory arthritis or pseudogout of the study joint;
Cancer/metastatic disease;
Systemic or intra-articular corticosteroid use within 60 days of the
Screening visit;
Known sensitivity to any of the ingredients listed in the treatments under
investigation;
Significant medical and skin conditions which, in the opinion of the
investigator, will interfere with study participation and patch adherence;
Replacement of the knee joint.
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patients for primary and secondary endpoints will be
blinded to patient treatment assignment. The investiga-
tors, therapists and assessors are different people.
Endpoints
The primary efficacy endpoint of the study will be Wes-
tern Ontario and McMaster Universities Index of OA
(WOMAC) [15] total score at Day14 and Day 28.
Secondary efficacy endpoints are : i) patient global
assessment of response to treatment; ii) patient global
assessment of OA condition; iii) WOMAC pain, stiff-
ness, and physical function subscales; iv) investigator
global assessment of response to treatment; v) investiga-
tor global assessment of OA condition; vi) TCM assess-
ment of OA condition measured by syndromes
questionnaire (Table 4); vii)SF-36 assessment.
Safety assessments
Spontaneously reported adverse events will be recorded
throughout the study. Vital signs will be monitored at
every visit. Laboratory investigations including haema-
tology, blood chemistry and urinalysis will be performed
at Day 0 and Day 28, and repeated on a need basis. For
all adverse events the intensity, relation to test drug, and
actions taken will be recorded. All adverse events
including reports of skin irritation will be followed until
resolution of the event occurs.
Sample size
Sample size calculations were based on published data
[5,14,16]. The mean differences in WOMAC scores before
and after treatment with the integrative TCM approach,
counter osteophytes capsule, Fufang Zijin patch, acupunc-
ture and Tuina are 11 (SD = 5), 12 (SD = 6), 9.34 (SD =
4.09), 10.17 (SD = 3.85) and 8.89 (SD = 4.32), respectively.
Using these data we estimated that 420 patients would be
sufficient to give 0.8 power at 0.05 alpha level. Allowing
for dropout, we plan to enroll 500 patients.
Analysis plan
The Biometrics and Clinical Data Systems Department
at the China Academy of Chinese Medical Sciences will
be responsible for the data management and statistical
analysis of this study.




1 The therapist using grasping or rolling applies to the back of the thigh and the crus for 2 minutes.
2 Pushing, kneading or pushing with one-finger meditation on popliteal fossa for 2 minutes.
3 Rolling applies to tensor fascia lata, quadriceps and adductors in the limb for 3 minutes.
4 Rubbing, kneading or pushing with one-finger meditation applies to the Dubi(ST35), Neixiyan(EX-LE5), Ashi points, and each
acupoint is about 40 seconds.
5 Gently Pushing the patella to the upward, downward, inward and outward directions for several times, then to the extreme limit
of patella and maintaining for 2 and 3 seconds. Repeat 3 times.
6 Pulling the knee. The assistant helps fix the distal thigh, and the therapist uses hands to hold the distal leg and pull for 2
seconds. Repeat 5 times.
7 Passive flexion and extension, adduction and abduction of hip and knee joint to the utmost degree that patient can stand.
Repeat 3 times.
Description: The power of tuina manipulation requires evenly and gently application to the degree that patients feel comfort and tolerance. In operations 1 and
2, the patient remains in the prone position. In operations 3 through 7, the patient assumes the supine position.
Dose: about 20 minutes each time and 2 times per week.
Table 3 Individually Integrated TCM approach for knee OA
Approach content WOMAC scoring
counter osteophytes capsule all scoring < 40 mm
counter osteophytes capsule + acupuncture any one in 5 pain subscales ≥ 40 mm
counter osteophytes capsule + Fufang Zijin patch any one in 2 stiffness subscales ≥ 40 mm
counter osteophytes capsule + Tuina any one in 17 physical function subscales ≥ 40 mm
counter osteophytes capsule + acupuncture + Fufnag
Zijin patch
both at least one in 5 pain subscales and at least one in 2 stiffness subscales ≥ 40 mm
counter osteophytes capsule + acupuncture + Tuina both at least one in 5 pain subscales and at least one in 17 physical function subscales ≥
40 mm
counter osteophytes capsule + Fufang Zijin patch +
Tuina
both at least one in 2 stiffness subscales and at least one in 17 physical function
subscales ≥ 40 mm
counter osteophytes capsule + acupuncture + Fufang
Zijin patch + Tuina
at least one in 5 pain subscales and one in 2 stiffness subscales and one in 17 physical
function subscales ≥ 40 mm
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Demographic and baseline variables will be compared
across treatment groups using Analysis of Variance
(ANOVA) for continuous variables and the chi-square test
for categorical variables. If the expected number of sub-
jects within a specific category is sufficiently small, Fisher’s
exact test will be used in place of the chi-square test.
Efficacy analysis
The primary efficacy analysis will be based on the full
analysis set, defined as all randomized subjects who
have baseline and at least one post-baseline efficacy
assessment. OA trials are prone to dropouts related to
treatment (e.g., inadequate response or intolerance) and
because such dropouts will not be at random, thus stan-
dard imputation methods are inapplicable. Therefore,
we will conduct sensitivity analysis described below
wherein missing data are imputed to increasingly
adverse degrees to explore whether the primary result
still stands. As a supportive analysis, efficacy will also be
assessed based on the per protocol set, defined patients
in the full analysis set who have no major protocol vio-
lation. Statistical comparisons for total and subscale
scores based on the WOMAC will be made using a
repeated-measure mixed model with terms for treat-
ment, day, center, and baseline value as covariate. The
within-subject covariance structure will be assumed
unstructured. Treatment-by-day and day-by-baseline
interactions will be included in order to compare the
treatment difference at each assessment time point as
well as for the average across time points. The treat-
ment difference and its 95% confidence interval will be
estimated from this model. The same approach will be
used for analyzing the Patient Global Assessment of OA
condition and the Investigator Global Assessment of
OA condition. A similar approach will be used for ana-
lysis of Patient and Investigator Global Assessments of
response to treatment, but without inclusion of a base-
line covariate and associated interaction terms.
Sensitivity analysis
In this analysis missing data for patients prematurely
discontinuing from the trial (or for patients for other
reasons not included in the full analysis set) are gener-
ated by random draw from the completer patient data,
then adjusted as described below. The analysis is
described for a situation where treatment A is statisti-
cally significantly superior to treatment B by the primary
efficacy analysis. The treatment effect is the difference of
the WOMAC change in the treatment A and the
WOMAC change in treatment B. Call this treatment
effect difference D. Four scenarios are investigated, cor-
responding to the loss of 25%, 50%, 75%, and 100% of
the treatment effect difference. Patients that prematurely
discontinued from treatment A will have their WOMAC
change values determined by random draw (with repla-
cement) from the treatment A completers, then these
values are adjusted downward by 1/8*D, 2/8*D, 3/8*D,
then 4/8*D, for the 1st, 2nd, 3rd, and 4th scenario, respec-
tively. Treatment B dropouts will have their random
draw values adjusted upward sequentially by the same
factors (1/8*D, 2/8*D, 3/8*D, then 4/8*D). The four sce-
narios, therefore, are:
#1-Assuming loss of 25% of the treatment effect; this
is the least adverse scenario.
#2-Assuming loss of 50% of the treatment effect
seen in completers.
#3-Assuming loss of 75% of the treatment effect
seen in completers.
Table 4 Syndromes questionnaire for TCM assessment of
knee OA condition
Tongue color (choose one with √ or note for others)
pale tongue □








Tongue fur (choose one with √ or note for others)
white fur □
yellow fur □
thin fur □ thin fur □ others
(please
note)








































Whole body situation (mark with √ for yes or no)
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#4-Assuming loss of 100% of the treatment effect;
this is the most adverse scenario.
Because the analysis involves stochastic variables, it
will be repeated 100 times in order to better estimate
the means and approximate 95% confidence intervals.
The following treatment comparisons will be per-
formed based on the repeated measures mixed model
and sensitivity analysis:i) Comparison at each of Days 0,
14, and 28;ii) Comparison of the Day 14 and 28
averages, using the time-averaged Day 14 and 28 scores
estimated within the model framework;iii) Comparison
of the average over all post-treatment days, using the
time-averaged Day 14 and 28 scores estimated within
the model framework;iv)All statistical tests will be two-
sided. The primary endpoint and key secondary end-
points will be tested.
Data integrity and management
Data will be stored electronically on a database with
secured and restricted access. Data transfer will be
encrypted and any information capable of identifying
individuals removed.
Withdrawal
A participant will be considered to have withdrawn from
the trial when consent is revoked (except to ask permis-
sion for a determination of a final withdrawal visit
WOMAC score) or if the participant cannot be con-
tacted or located. If this occurs, no further assessments
will be performed. Participants will not be withdrawn
from the trial for protocol violations. Withdrawal due to
adverse event should be distinguished from withdrawal
due to insufficient response. When a subject withdraws
due to a serious adverse event, the serious adverse event
must be reported in accordance with the reporting
requirements.
Monitoring
The trial will be overseen and monitored by a program
manager. The program manager will visit each site to
examine trial procedures, ensure data quality and moni-
tor compliance with the trial protocol.
Discussion
The biggest limitation of this study is the lack of pla-
cebo control. It should be noted that the aim of this
trial is not to estimate the efficacy of treatments used,
but to demonstrate that individually integrated TCM
approach is superior to individual component alone.
This aim arises from clinical experience. The compo-
nents of these treatments have been used for centuries.
TCM has over 2000 years’ application in China, usually
as “one method applied in a whole course of treatment”.
However, even though the individual approach, based
on different features of OA, is recommended, there is
no evidence that it is superior to a treatment compo-
nent used alone.
In an OA trial, a statistically significant result might
be due to the dropout pattern rather than a true treat-
ment effect, so we are attempting to collect data at the
time of discontinuation to enable better comparisons of
those completing versus those discontinuing. Addition-
ally, we are conducting a formal sensitivity analysis
using imputed data for discontinued patients to deter-
mine whether a positive result remains positive in sce-
narios where part or all of the treatment effect
difference seen in the completers is lost in the dropout
patients. To our knowledge, this is the first trial in a
chronic symptomatic disorder to explicitly specify this
type of sensitivity analysis to address trial dropouts.
Our results will be conditional on the population
recruited, and the patients we recruited, requiring pain
intensity of 20 mm or more on visual analogue scales
(VAS), may have larger or smaller responses to treat-
ment compared to those without such a restriction. For
example, it was recently shown that use of a “flare” to
define trial eligibility in OA alters, on average, response
to treatment [17]. Another limitation is no double-blind-
ing. Although it is difficult to carry out double-blinding
in this design, we blind those clinicians conducting the
assessments to decrease possible bias. The study also
lacks long-term follow-up and evaluation. However, the
duration chosen in the present study is consistent with
acute OA flare episodes; and the study is long enough
to document a rapid onset of a treatment modality and
its efficacy sustained for 4 weeks. The protocol has a
provision for rescue medication although its use is
discouraged.
OA diagnosis is made based on objective radiological
criteria along with excluding inection or gout, and it
made using the medical history and physical exam. The
WOMAC index is a validated scale that uses 24 para-
meters to assess OA of the hip or knee with focus on
Pain, Stiffness, Physical Function, Social Function and
Emotional Function [18,19]. The design of this study is
consistent with both global clinical research standards
and use of TCM criteria for evaluating efficacy and
safety. One important principle guiding TCM therapy is
to use drug treatment according to “Syndromes”. Syn-
drome is different from the disease name, since it is a
summarized analysis of the symptom data from patients’
whole situation using TCM methods. It may not only
include local symptoms which are part of the disease
but also symptoms from the whole body situation.
Given the differences in the whole body situation in dif-
ferent people, it is natural that OA, a kind of disease,
has different Syndromes. In TCM, OA is known as Bi,
Yuelong et al. Trials 2011, 12:160
http://www.trialsjournal.com/content/12/1/160
Page 6 of 8
Wei, Ganshen kuixu, or Jinmai yuzhi Syndrome and so
on [20].
WOMAC questionnaires are detailed in the descrip-
tion of local symptoms of OA, while the Syndromes
questionnaires more emphasizes the body’s whole situa-
tion. Thus, the result of this research could also provide
information on the correlation of symptoms-analysis
gathered from WOMAC and Syndromes of TCM in dif-
ferent phases (mild, moderate or severe) of OA which
may be helpful for predicting severity of OA using TCM
methods.
Given the use of two manipulative methods (acupunc-
ture, Tuina) in this study, patients’ compliance and
response to treatment is critical to the treatment effect.
WOMAC subscale analysis will provide information on
which OA symptom (pain, stiffness, or function) was
more responsive to which treatment. Since this is an
East meet West study, outcome measures capture both
OA symptoms and the whole body TCM assessment
according to TCM theory. We also include a standard
quality of life measure, the SF-36, as in many other OA
trials [21,22].
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